Gerd Zettlmeissl

Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA.

Intercell AG engages in the research, development, manufacture, and marketing of novel vaccines for the prevention and treatment of infectious diseases. Its products include Japanese encephalitis vaccine, Pseudomonas vaccine, Clostridium difficile vaccine, tuberculosis vaccine, and pandemic influenza vaccine patch. Its technology platforms involve patch-based delivery system and proprietary human monoclonal antibody discovery system. The company was founded by Alexander von Gabain, Max Birnstiel, Michael Buschle, Walter Schmidt, and Aaron Hirsh on December 3, 1997 and is headquartered in Vienna, Austria.

Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD.

Part of Novartis AG, Chiron Behring & Co. is a German company that supplies and develops new vaccine products for adults and children. The company is based in Marburg, Germany. Chiron Behring was acquired by Chiron Corp. from Hoechst AG on April 01, 1998 for $111.90 million.

GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.